A detailed history of Capital Research Global Investors transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Capital Research Global Investors holds 9,002,205 shares of VRTX stock, worth $3.58 Billion. This represents 0.9% of its overall portfolio holdings.

Number of Shares
9,002,205
Previous 8,539,339 5.42%
Holding current value
$3.58 Billion
Previous $4 Billion 4.6%
% of portfolio
0.9%
Previous 0.9%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$460.0 - $505.78 $213 Million - $234 Million
462,866 Added 5.42%
9,002,205 $4.19 Billion
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $1.1 Billion - $1.36 Billion
2,795,457 Added 48.67%
8,539,339 $4 Billion
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $887 Million - $971 Million
2,176,218 Added 61.0%
5,743,882 $2.4 Billion
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $66.9 Million - $80.1 Million
195,080 Added 5.78%
3,567,664 $1.45 Billion
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $105 Million - $113 Million
310,908 Added 10.15%
3,372,584 $1.17 Billion
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $708 Million - $792 Million
2,251,781 Added 278.03%
3,061,676 $1.08 Billion
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $229 Million - $262 Million
809,895 New
809,895 $255 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $259 Million - $345 Million
-1,250,658 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $255 - $303
-1 Reduced -0.0%
1,250,658 $340 Million
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $1,127 - $1,479
-5 Reduced -0.0%
1,250,659 $363 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $2,996 - $3,717
15 Added 0.0%
1,250,664 $298 Million
Q4 2019

Feb 18, 2020

BUY
$166.71 - $223.91 $63,183 - $84,861
379 Added 0.03%
1,250,649 $274 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $3,657 - $4,115
22 Added 0.0%
1,250,270 $212 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $40,823 - $47,211
248 Added 0.02%
1,250,248 $229 Million
Q1 2019

May 15, 2019

SELL
$163.73 - $194.7 $133 Million - $159 Million
-815,018 Reduced 39.47%
1,250,000 $230 Million
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $89.6 Million - $113 Million
-590,000 Reduced 22.22%
2,065,018 $342 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $445 Million - $512 Million
2,655,018 New
2,655,018 $512 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Capital Research Global Investors Portfolio

Follow Capital Research Global Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital Research Global Investors with notifications on news.